Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.

Ferdinandos Skoulidis, MD, PhD, explores emerging KRAS-targeted therapies in KRAS-mutated non–small cell lung cancer.

Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and ...

The FDA granted final approval to Alembic's generic venetoclax tablets, rated therapeutically equivalent to Venclexta, for CLL/SLL and newly diagnosed AML.

Merieme Klobocista, MD, explains how surgical history, disease burden, and body habits guide minimally invasive surgery decisions in gynecologic cancer.

Obesity and lung cancer research shows mixed results; experts urge moving beyond BMI to waist metrics and CT-based body ...

Merieme Klobocista, MD, of Hackensack Meridian Health explains how molecular testing is personalizing treatment for ovarian ...

Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for ...

ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab ...

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as ...

The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall ...

Real-world study shows outpatient tarlatamab for relapsed SCLC is feasible, with mostly low-grade CRS, rare ICANS, low ICU ...